Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome

Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's syndrome), which is characterized by a mildly elevated blood bilirubin concentration. The established antioxidant effect of bilirubin, howeve...

Full description

Saved in:
Bibliographic Details
Published inClinical science (1979) Vol. 125; no. 5; pp. 257 - 264
Main Authors Wallner, Marlies, Marculescu, Rodrig, Doberer, Daniel, Wolzt, Michael, Wagner, Oswald, Vitek, Libor, Bulmer, Andrew C., Wagner, Karl-Heinz
Format Journal Article
LanguageEnglish
Published England 01.09.2013
Subjects
Online AccessGet full text
ISSN0143-5221
1470-8736
1470-8736
DOI10.1042/CS20120661

Cover

Abstract Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's syndrome), which is characterized by a mildly elevated blood bilirubin concentration. The established antioxidant effect of bilirubin, however, contributes only in part to this protection. Therefore we investigated whether mildly elevated circulating UCB (unconjugated bilirubin) is associated with altered lipid metabolism. The study was performed on GS and age- and gender-matched healthy subjects (n=59 per group). Full lipoprotein profile, TAG (triacylglycerols), Apo (apolipoprotein)-A1, Apo-B, lipoprotein(a), the subfractions of LDL (low-density lipoprotein) and selected pro-inflammatory mediators were analysed. A hyperbilirubinaemic rodent model (Gunn rats, n=40) was investigated to further support the presented human data. GS subjects had significantly (P<0.05) improved lipid profile with reduced total cholesterol, LDL-C (LDL-cholesterol), TAG, low- and pro-atherogenic LDL subfractions (LDL-1+LDL-2), Apo-B, Apo-B/Apo-A1 ratio and lower IL-6 (interleukin 6) and SAA (serum amyloid A) concentrations (P=0.094). When the control and GS groups were subdivided into younger and older cohorts, older GS subjects demonstrated reduced lipid variables (total cholesterol and LDL-C, TAG and LDL-C subfractions, Apo-B/Apo-A1 ratio; P<0.05; Apo-B: P<0.1) compared with controls. These data were supported by lipid analyses in the rodent model showing that Gunn rat serum had lower total cholesterol (2.29±0.38 compared with 1.27±0.72 mM; P<0.001) and TAG (1.66±0.67 compared with 0.99±0.52 mM; P<0.001) concentrations compared with controls. These findings indicate that the altered lipid profile and the reduced pro-inflammatory status in hyperbilirubinaemic subjects, particularly in the older individuals, probably contribute additionally to the commonly accepted beneficial antioxidant effects of bilirubin in humans.
AbstractList Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's syndrome), which is characterized by a mildly elevated blood bilirubin concentration. The established antioxidant effect of bilirubin, however, contributes only in part to this protection. Therefore we investigated whether mildly elevated circulating UCB (unconjugated bilirubin) is associated with altered lipid metabolism. The study was performed on GS and age- and gender-matched healthy subjects (n=59 per group). Full lipoprotein profile, TAG (triacylglycerols), Apo (apolipoprotein)-A1, Apo-B, lipoprotein(a), the subfractions of LDL (low-density lipoprotein) and selected pro-inflammatory mediators were analysed. A hyperbilirubinaemic rodent model (Gunn rats, n=40) was investigated to further support the presented human data. GS subjects had significantly (P<0.05) improved lipid profile with reduced total cholesterol, LDL-C (LDL-cholesterol), TAG, low- and pro-atherogenic LDL subfractions (LDL-1+LDL-2), Apo-B, Apo-B/Apo-A1 ratio and lower IL-6 (interleukin 6) and SAA (serum amyloid A) concentrations (P=0.094). When the control and GS groups were subdivided into younger and older cohorts, older GS subjects demonstrated reduced lipid variables (total cholesterol and LDL-C, TAG and LDL-C subfractions, Apo-B/Apo-A1 ratio; P<0.05; Apo-B: P<0.1) compared with controls. These data were supported by lipid analyses in the rodent model showing that Gunn rat serum had lower total cholesterol (2.29±0.38 compared with 1.27±0.72 mM; P<0.001) and TAG (1.66±0.67 compared with 0.99±0.52 mM; P<0.001) concentrations compared with controls. These findings indicate that the altered lipid profile and the reduced pro-inflammatory status in hyperbilirubinaemic subjects, particularly in the older individuals, probably contribute additionally to the commonly accepted beneficial antioxidant effects of bilirubin in humans.
Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's syndrome), which is characterized by a mildly elevated blood bilirubin concentration. The established antioxidant effect of bilirubin, however, contributes only in part to this protection. Therefore we investigated whether mildly elevated circulating UCB (unconjugated bilirubin) is associated with altered lipid metabolism. The study was performed on GS and age- and gender-matched healthy subjects (n=59 per group). Full lipoprotein profile, TAG (triacylglycerols), Apo (apolipoprotein)-A1, Apo-B, lipoprotein(a), the subfractions of LDL (low-density lipoprotein) and selected pro-inflammatory mediators were analysed. A hyperbilirubinaemic rodent model (Gunn rats, n=40) was investigated to further support the presented human data. GS subjects had significantly (P<0.05) improved lipid profile with reduced total cholesterol, LDL-C (LDL-cholesterol), TAG, low- and pro-atherogenic LDL subfractions (LDL-1+LDL-2), Apo-B, Apo-B/Apo-A1 ratio and lower IL-6 (interleukin 6) and SAA (serum amyloid A) concentrations (P=0.094). When the control and GS groups were subdivided into younger and older cohorts, older GS subjects demonstrated reduced lipid variables (total cholesterol and LDL-C, TAG and LDL-C subfractions, Apo-B/Apo-A1 ratio; P<0.05; Apo-B: P<0.1) compared with controls. These data were supported by lipid analyses in the rodent model showing that Gunn rat serum had lower total cholesterol (2.29±0.38 compared with 1.27±0.72 mM; P<0.001) and TAG (1.66±0.67 compared with 0.99±0.52 mM; P<0.001) concentrations compared with controls. These findings indicate that the altered lipid profile and the reduced pro-inflammatory status in hyperbilirubinaemic subjects, particularly in the older individuals, probably contribute additionally to the commonly accepted beneficial antioxidant effects of bilirubin in humans.
Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's syndrome), which is characterized by a mildly elevated blood bilirubin concentration. The established antioxidant effect of bilirubin, however, contributes only in part to this protection. Therefore we investigated whether mildly elevated circulating UCB (unconjugated bilirubin) is associated with altered lipid metabolism. The study was performed on GS and age- and gender-matched healthy subjects (n=59 per group). Full lipoprotein profile, TAG (triacylglycerols), Apo (apolipoprotein)-A1, Apo-B, lipoprotein(a), the subfractions of LDL (low-density lipoprotein) and selected pro-inflammatory mediators were analysed. A hyperbilirubinaemic rodent model (Gunn rats, n=40) was investigated to further support the presented human data. GS subjects had significantly (P<0.05) improved lipid profile with reduced total cholesterol, LDL-C (LDL-cholesterol), TAG, low- and pro-atherogenic LDL subfractions (LDL-1+LDL-2), Apo-B, Apo-B/Apo-A1 ratio and lower IL-6 (interleukin 6) and SAA (serum amyloid A) concentrations (P=0.094). When the control and GS groups were subdivided into younger and older cohorts, older GS subjects demonstrated reduced lipid variables (total cholesterol and LDL-C, TAG and LDL-C subfractions, Apo-B/Apo-A1 ratio; P<0.05; Apo-B: P<0.1) compared with controls. These data were supported by lipid analyses in the rodent model showing that Gunn rat serum had lower total cholesterol (2.29±0.38 compared with 1.27±0.72 mM; P<0.001) and TAG (1.66±0.67 compared with 0.99±0.52 mM; P<0.001) concentrations compared with controls. These findings indicate that the altered lipid profile and the reduced pro-inflammatory status in hyperbilirubinaemic subjects, particularly in the older individuals, probably contribute additionally to the commonly accepted beneficial antioxidant effects of bilirubin in humans.Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's syndrome), which is characterized by a mildly elevated blood bilirubin concentration. The established antioxidant effect of bilirubin, however, contributes only in part to this protection. Therefore we investigated whether mildly elevated circulating UCB (unconjugated bilirubin) is associated with altered lipid metabolism. The study was performed on GS and age- and gender-matched healthy subjects (n=59 per group). Full lipoprotein profile, TAG (triacylglycerols), Apo (apolipoprotein)-A1, Apo-B, lipoprotein(a), the subfractions of LDL (low-density lipoprotein) and selected pro-inflammatory mediators were analysed. A hyperbilirubinaemic rodent model (Gunn rats, n=40) was investigated to further support the presented human data. GS subjects had significantly (P<0.05) improved lipid profile with reduced total cholesterol, LDL-C (LDL-cholesterol), TAG, low- and pro-atherogenic LDL subfractions (LDL-1+LDL-2), Apo-B, Apo-B/Apo-A1 ratio and lower IL-6 (interleukin 6) and SAA (serum amyloid A) concentrations (P=0.094). When the control and GS groups were subdivided into younger and older cohorts, older GS subjects demonstrated reduced lipid variables (total cholesterol and LDL-C, TAG and LDL-C subfractions, Apo-B/Apo-A1 ratio; P<0.05; Apo-B: P<0.1) compared with controls. These data were supported by lipid analyses in the rodent model showing that Gunn rat serum had lower total cholesterol (2.29±0.38 compared with 1.27±0.72 mM; P<0.001) and TAG (1.66±0.67 compared with 0.99±0.52 mM; P<0.001) concentrations compared with controls. These findings indicate that the altered lipid profile and the reduced pro-inflammatory status in hyperbilirubinaemic subjects, particularly in the older individuals, probably contribute additionally to the commonly accepted beneficial antioxidant effects of bilirubin in humans.
Author Vitek, Libor
Wagner, Oswald
Wagner, Karl-Heinz
Bulmer, Andrew C.
Wolzt, Michael
Wallner, Marlies
Marculescu, Rodrig
Doberer, Daniel
Author_xml – sequence: 1
  givenname: Marlies
  surname: Wallner
  fullname: Wallner, Marlies
  organization: Department of Nutritional Sciences, Emerging Field ‘Oxidative Stress and DNA Stability’ and Research Platform ‘Active Ageing’, University of Vienna, Vienna, Austria
– sequence: 2
  givenname: Rodrig
  surname: Marculescu
  fullname: Marculescu, Rodrig
  organization: Clinical Institute of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
– sequence: 3
  givenname: Daniel
  surname: Doberer
  fullname: Doberer, Daniel
  organization: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
– sequence: 4
  givenname: Michael
  surname: Wolzt
  fullname: Wolzt, Michael
  organization: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
– sequence: 5
  givenname: Oswald
  surname: Wagner
  fullname: Wagner, Oswald
  organization: Clinical Institute of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
– sequence: 6
  givenname: Libor
  surname: Vitek
  fullname: Vitek, Libor
  organization: 4th Department of Internal Medicine and Institute of Medical Biochemistry and Laboratory Medicine, Charles University in Prague, Prague, Czech Republic
– sequence: 7
  givenname: Andrew C.
  surname: Bulmer
  fullname: Bulmer, Andrew C.
  organization: Heart Foundation Research Centre, Griffith Health Institute, Griffith University, Southport, Australia
– sequence: 8
  givenname: Karl-Heinz
  surname: Wagner
  fullname: Wagner, Karl-Heinz
  organization: Department of Nutritional Sciences, Emerging Field ‘Oxidative Stress and DNA Stability’ and Research Platform ‘Active Ageing’, University of Vienna, Vienna, Austria, Heart Foundation Research Centre, Griffith Health Institute, Griffith University, Southport, Australia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23566065$$D View this record in MEDLINE/PubMed
BookMark eNptkV1rFTEQhoNU7Gn1xh8guVOE1cnnbi_loFUotFC9XmaTORLNbo5JttB_0J9t-kVBZC4yF8_7zuSdI3awpIUYey3ggwAtP24vJQgJ1opnbCN0D93QK3vANiC06oyU4pAdlfILQKpWL9ihVMZasGbDbi5yquRqSAvf5TRz_EldpoiVPA-Ly4SFWsNj2AfPp5BmzL8pF47LLbCLOM94J3dpqTlMa6XCa-IOsw_pCotbI2a-f5rT3E5DnCjXt4WX68W3ufSSPd9hLPTq4T1mP758_r792p2dn37bfjrrnDKqdnYAOhncJDRpgZPR3gzgUaD3vXHgqaVgB-EU9aQJZI8gTzyZQQ89wYDqmL27920L_Vmp1HEOxVGMuFBayyiUERYGoWVD3zyg6zSTH_c5tM9fj4_pNQDuAZdTKZl2owv1LoyaMcRRwHh7oPHpQE3y_h_Jo-t_4L8JiZIg
CitedBy_id crossref_primary_10_1186_1742_4933_11_11
crossref_primary_10_3390_nu7021352
crossref_primary_10_1158_1940_6207_CAPR_13_0125
crossref_primary_10_1038_s41598_017_00933_y
crossref_primary_10_1016_j_molmed_2023_01_007
crossref_primary_10_1042_CS20140566
crossref_primary_10_1038_srep15482
crossref_primary_10_1016_j_trre_2018_06_003
crossref_primary_10_1016_j_metabol_2021_154913
crossref_primary_10_1152_ajprenal_00039_2014
crossref_primary_10_1186_s12916_020_01703_w
crossref_primary_10_1186_s12933_022_01484_x
crossref_primary_10_3389_fphar_2020_594574
crossref_primary_10_1186_s12944_023_01979_w
crossref_primary_10_1055_a_2237_8863
crossref_primary_10_3389_fphar_2020_636533
crossref_primary_10_1097_MD_0000000000017544
crossref_primary_10_1016_j_etap_2023_104321
crossref_primary_10_1038_srep09886
crossref_primary_10_1152_ajpendo_00405_2020
crossref_primary_10_1016_j_clinbiochem_2014_08_008
crossref_primary_10_1016_j_freeradbiomed_2015_08_020
crossref_primary_10_1016_j_atherosclerosis_2014_12_042
crossref_primary_10_1016_j_bj_2019_12_004
crossref_primary_10_3390_cancers15184584
crossref_primary_10_1016_j_cca_2016_12_020
crossref_primary_10_1042_CS20242825
crossref_primary_10_1515_anre_2017_0024
crossref_primary_10_3109_00365513_2015_1031691
crossref_primary_10_1186_1475_2840_12_166
crossref_primary_10_1016_j_lfs_2020_118032
crossref_primary_10_3389_fendo_2021_792795
crossref_primary_10_1016_j_tem_2018_01_002
crossref_primary_10_3390_antiox10091474
crossref_primary_10_3390_nu8060338
crossref_primary_10_3390_biom13020252
crossref_primary_10_1152_ajpgi_00026_2018
crossref_primary_10_1371_journal_pone_0079073
crossref_primary_10_1080_10408363_2018_1428526
crossref_primary_10_1177_0003319716660240
crossref_primary_10_1152_ajpheart_00417_2017
crossref_primary_10_1038_s41537_024_00473_1
crossref_primary_10_1016_j_metabol_2024_156081
crossref_primary_10_3389_fcvm_2022_822626
crossref_primary_10_3892_etm_2018_6184
crossref_primary_10_1161_JAHA_117_005520
crossref_primary_10_1016_j_isci_2024_110234
crossref_primary_10_1152_physiolgenomics_00028_2019
crossref_primary_10_1016_j_atherosclerosis_2014_12_053
crossref_primary_10_1097_j_pbj_0000000000000275
crossref_primary_10_1111_eci_12120
crossref_primary_10_1080_09537104_2017_1280146
crossref_primary_10_1038_srep30051
crossref_primary_10_1016_j_clinbiochem_2015_06_016
crossref_primary_10_1155_2014_175286
crossref_primary_10_1007_s10072_020_04268_x
crossref_primary_10_1038_srep22300
crossref_primary_10_3390_medicina59101837
crossref_primary_10_1161_HYPERTENSIONAHA_118_11130
crossref_primary_10_1016_j_atherosclerosis_2015_11_008
crossref_primary_10_1089_ars_2013_5667
crossref_primary_10_2174_1567202616666190412153735
crossref_primary_10_3389_fcvm_2022_967097
crossref_primary_10_3389_fphar_2021_646953
crossref_primary_10_1186_1472_6823_13_39
crossref_primary_10_2478_jomb_2014_0058
crossref_primary_10_1186_s12872_022_02899_w
crossref_primary_10_1016_j_atherosclerosis_2014_05_927
crossref_primary_10_3389_fcimb_2021_701109
crossref_primary_10_3390_jcm10132812
crossref_primary_10_1113_JP282395
crossref_primary_10_1152_ajpendo_00396_2016
crossref_primary_10_1007_s11906_019_0994_z
crossref_primary_10_1016_j_pharmthera_2021_107975
Cites_doi 10.1161/01.CIR.0000115516.54550.B1
10.1371/journal.pone.0018582
10.1194/jlr.R200004-JLR200
10.2215/CJN.06130710
10.1111/j.1365-2796.2006.01643.x
10.1089/jwh.2010.2453
10.1016/j.jacl.2011.02.001
10.1038/nature05487
10.1093/clinchem/47.2.266
10.1016/j.freeradbiomed.2012.03.002
10.1016/j.numecd.2011.03.001
10.1515/cclm.2011.662
10.1165/rcmb.2009-0170TR
10.1371/journal.pmed.0030287
10.1111/j.1478-3231.2008.01821.x
10.1002/hep.1840400412
10.1016/j.atherosclerosis.2007.11.022
10.1016/j.clinbiochem.2010.12.003
10.1001/jama.286.3.327
10.5551/jat.6346
10.1016/j.metabol.2009.04.003
10.1111/j.1582-4934.2010.01098.x
10.1056/NEJM199511023331802
10.1124/dmd.110.035030
10.1016/0891-5849(95)00032-S
10.1001/jama.2011.124
10.1002/ajmg.10209
10.1001/jama.2009.1619
10.1093/clinchem/40.1.18
10.1023/A:1013794407325
10.1016/j.plipres.2012.11.001
10.1111/j.1365-2796.2008.02016.x
10.1177/15353702-0322805-29
10.1161/CIRCULATIONAHA.104.528802
10.1097/MOL.0b013e3283488c39
10.1016/j.numecd.2007.02.010
10.1111/j.1440-1746.2006.04564.x
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1042/CS20120661
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1470-8736
EndPage 264
ExternalDocumentID 23566065
10_1042_CS20120661
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
0R~
0VX
29B
2WC
4.4
5GY
5RE
5VS
6J9
AAYXX
ABCQX
ABJNI
ACGFO
ACGFS
ADBBV
AEGXH
AENEX
AIAGR
AIZAD
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CITATION
CS3
DU5
E3Z
EBD
EBS
EJD
EMOBN
F5P
GX1
H13
HZ~
L7B
MV1
NTEUP
O9-
P2P
P6G
RHI
RPO
SV3
TR2
WH7
.55
.GJ
3O-
53G
AABGO
AAHRG
AFFNX
AFFVI
AI.
CGR
CUY
CVF
ECM
EIF
MVM
NPM
OHT
VH1
X7M
ZGI
ZXP
7X8
ID FETCH-LOGICAL-c353t-680e98cb14e41ab54d580da1add75c0de661681c3e7e4e027a029de58487e08a3
ISSN 0143-5221
1470-8736
IngestDate Fri Jul 11 12:02:02 EDT 2025
Thu Jan 02 22:11:05 EST 2025
Tue Jul 01 03:56:50 EDT 2025
Thu Apr 24 22:54:46 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c353t-680e98cb14e41ab54d580da1add75c0de661681c3e7e4e027a029de58487e08a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 23566065
PQID 1351608142
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_1351608142
pubmed_primary_23566065
crossref_citationtrail_10_1042_CS20120661
crossref_primary_10_1042_CS20120661
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-09-01
PublicationDateYYYYMMDD 2013-09-01
PublicationDate_xml – month: 09
  year: 2013
  text: 2013-09-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Clinical science (1979)
PublicationTitleAlternate Clin Sci (Lond)
PublicationYear 2013
References Chowdhury (2021113010282006400_B20) 1993; 37
King (2021113010282006400_B25) 2011; 22
Otvos (2021113010282006400_B19) 2011; 5
Vitek (2021113010282006400_B33) 2007; 22
Chen (2021113010282006400_B5) 2011; 6
Muchova (2021113010282006400_B10) 2011; 15
Walldius (2021113010282006400_B39) 2006; 259
Dennery (2021113010282006400_B11) 1995; 19
Bosma (2021113010282006400_B6) 1995; 333
Pradhan (2021113010282006400_B23) 2001; 286
Horsfall (2021113010282006400_B4) 2011; 305
Walldius (2021113010282006400_B40) 2007; 17
Zucker (2021113010282006400_B3) 2004; 40
Tapan (2021113010282006400_B17) 2011; 44
Yang (2021113010282006400_B24) 2006; 3
Hoefner (2021113010282006400_B26) 2001; 47
Novotny (2021113010282006400_B1) 2003; 228
Zhou (2021113010282006400_B35) 2011; 39
Bulmer (2021113010282006400_B9) 2008; 199
Choi (2021113010282006400_B28) 2013; 23
Johnson (2021113010282006400_B41) 2004; 109
Elmadfa (2021113010282006400_B27) 2009
Stocker (2021113010282006400_B8) 2004; 6
Emerging Risk Factors Collaboration (2021113010282006400_B21) 2009; 302
Andersson (2021113010282006400_B31) 2009; 58
Fertrin (2021113010282006400_B7) 2002; 108
Boon (2021113010282006400_B13) 2012; 52
Ocadlik (2021113010282006400_B18) 2011; 32
Holme (2021113010282006400_B38) 2009; 265
Temme (2021113010282006400_B2) 2001; 12
Ryter (2021113010282006400_B16) 2009; 41
Hwang (2021113010282006400_B42) 2011; 49
Kwon (2021113010282006400_B29) 2011; 20
Berneis (2021113010282006400_B36) 2002; 43
Bulmer (2021113010282006400_B30) 2012; 52
Lippi (2021113010282006400_B34) 2009; 29
Van Gaal (2021113010282006400_B22) 2006; 444
Leitzmann (2021113010282006400_B32) 2011; 6
Smith (2021113010282006400_B37) 2011; 58
Schwertner (2021113010282006400_B12) 1994; 40
Yoshino (2021113010282006400_B14) 2011; 18
Ollinger (2021113010282006400_B15) 2005; 112
References_xml – volume: 37
  start-page: 149
  year: 1993
  ident: 2021113010282006400_B20
  article-title: Gunn rat: a model for inherited deficiency of bilirubin glucuronidation
  publication-title: Adv. Vet. Sci. Comp. Med.
– volume: 109
  start-page: 726
  year: 2004
  ident: 2021113010282006400_B41
  article-title: Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE)
  publication-title: Circulation
  doi: 10.1161/01.CIR.0000115516.54550.B1
– volume-title: Austrian Nutrition Report 2008
  year: 2009
  ident: 2021113010282006400_B27
– volume: 6
  start-page: e18582
  year: 2011
  ident: 2021113010282006400_B32
  article-title: Waist circumference as compared with body-mass index in predicting mortality from specific causes
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0018582
– volume: 43
  start-page: 1363
  year: 2002
  ident: 2021113010282006400_B36
  article-title: Metabolic origins and clinical significance of LDL heterogeneity
  publication-title: J. Lipid Res.
  doi: 10.1194/jlr.R200004-JLR200
– volume: 6
  start-page: 567
  year: 2011
  ident: 2021113010282006400_B5
  article-title: Serum bilirubin links UGT1A1*28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients
  publication-title: Clin. J. Am. Soc. Nephrol.
  doi: 10.2215/CJN.06130710
– volume: 259
  start-page: 493
  year: 2006
  ident: 2021113010282006400_B39
  article-title: The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence
  publication-title: J. Intern. Med.
  doi: 10.1111/j.1365-2796.2006.01643.x
– volume: 20
  start-page: 963
  year: 2011
  ident: 2021113010282006400_B29
  article-title: Inverse association between total bilirubin and metabolic syndrome in rural Korean women
  publication-title: J. Womens Health
  doi: 10.1089/jwh.2010.2453
– volume: 5
  start-page: 105
  year: 2011
  ident: 2021113010282006400_B19
  article-title: Clinical implications of discordance between low-density lipoprotein cholesterol and particle number
  publication-title: J. Clin. Lipidol.
  doi: 10.1016/j.jacl.2011.02.001
– volume: 444
  start-page: 875
  year: 2006
  ident: 2021113010282006400_B22
  article-title: Mechanisms linking obesity with cardiovascular disease
  publication-title: Nature
  doi: 10.1038/nature05487
– volume: 47
  start-page: 266
  year: 2001
  ident: 2021113010282006400_B26
  article-title: Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System
  publication-title: Clin. Chem.
  doi: 10.1093/clinchem/47.2.266
– volume: 52
  start-page: 2120
  year: 2012
  ident: 2021113010282006400_B13
  article-title: Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome
  publication-title: Free Radical Biol. Med.
  doi: 10.1016/j.freeradbiomed.2012.03.002
– volume: 23
  start-page: 31
  year: 2013
  ident: 2021113010282006400_B28
  article-title: Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults
  publication-title: Nutr. Metab. Cardiovasc. Dis.
  doi: 10.1016/j.numecd.2011.03.001
– volume: 49
  start-page: 1823
  year: 2011
  ident: 2021113010282006400_B42
  article-title: Relationship between bilirubin and C-reactive protein
  publication-title: Clin. Chem. Lab. Med.
  doi: 10.1515/cclm.2011.662
– volume: 41
  start-page: 251
  year: 2009
  ident: 2021113010282006400_B16
  article-title: Heme oxygenase-1/carbon monoxide: from metabolism to molecular therapy
  publication-title: Am. J. Respir. Cell Mol. Biol.
  doi: 10.1165/rcmb.2009-0170TR
– volume: 3
  start-page: e287
  year: 2006
  ident: 2021113010282006400_B24
  article-title: Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications
  publication-title: PLoS Med.
  doi: 10.1371/journal.pmed.0030287
– volume: 29
  start-page: 315
  year: 2009
  ident: 2021113010282006400_B34
  article-title: Bilirubin concentration and cardiovascular risk profile
  publication-title: Liver Int.
  doi: 10.1111/j.1478-3231.2008.01821.x
– volume: 58
  start-page: 2432
  year: 2011
  ident: 2021113010282006400_B37
  article-title: AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association
  publication-title: Circulation
– volume: 40
  start-page: 827
  year: 2004
  ident: 2021113010282006400_B3
  article-title: Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer
  publication-title: Hepatology
  doi: 10.1002/hep.1840400412
– volume: 199
  start-page: 390
  year: 2008
  ident: 2021113010282006400_B9
  article-title: Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2007.11.022
– volume: 44
  start-page: 300
  year: 2011
  ident: 2021113010282006400_B17
  article-title: Decreased small dense LDL levels in Gilbert's syndrome
  publication-title: Clin. Biochem.
  doi: 10.1016/j.clinbiochem.2010.12.003
– volume: 286
  start-page: 327
  year: 2001
  ident: 2021113010282006400_B23
  article-title: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus
  publication-title: JAMA, J. Am. Med. Assoc.
  doi: 10.1001/jama.286.3.327
– volume: 18
  start-page: 403
  year: 2011
  ident: 2021113010282006400_B14
  article-title: Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients
  publication-title: J. Atheroscler. Thromb.
  doi: 10.5551/jat.6346
– volume: 58
  start-page: 1109
  year: 2009
  ident: 2021113010282006400_B31
  article-title: Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial
  publication-title: Metab., Clin. Exp.
  doi: 10.1016/j.metabol.2009.04.003
– volume: 15
  start-page: 1156
  year: 2011
  ident: 2021113010282006400_B10
  article-title: Bile acids decrease intracellular bilirubin levels in the cholestatic liver: implications for bile acid-mediated oxidative stress
  publication-title: J. Cell. Mol. Med.
  doi: 10.1111/j.1582-4934.2010.01098.x
– volume: 333
  start-page: 1171
  year: 1995
  ident: 2021113010282006400_B6
  article-title: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM199511023331802
– volume: 39
  start-page: 322
  year: 2011
  ident: 2021113010282006400_B35
  article-title: Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.110.035030
– volume: 19
  start-page: 395
  year: 1995
  ident: 2021113010282006400_B11
  article-title: Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia
  publication-title: Free Radical Biol. Med.
  doi: 10.1016/0891-5849(95)00032-S
– volume: 305
  start-page: 691
  year: 2011
  ident: 2021113010282006400_B4
  article-title: Serum bilirubin and risk of respiratory disease and death
  publication-title: JAMA, J. Am. Med. Assoc.
  doi: 10.1001/jama.2011.124
– volume: 108
  start-page: 117
  year: 2002
  ident: 2021113010282006400_B7
  article-title: Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil
  publication-title: Am. J. Med. Genet.
  doi: 10.1002/ajmg.10209
– volume: 302
  start-page: 1993
  year: 2009
  ident: 2021113010282006400_B21
  article-title: Major lipids, apolipoproteins, and risk of vascular disease
  publication-title: JAMA, J. Am. Med. Assoc.
  doi: 10.1001/jama.2009.1619
– volume: 40
  start-page: 18
  year: 1994
  ident: 2021113010282006400_B12
  article-title: Association of low serum concentration of bilirubin with increased risk of coronary artery disease
  publication-title: Clin. Chem.
  doi: 10.1093/clinchem/40.1.18
– volume: 12
  start-page: 887
  year: 2001
  ident: 2021113010282006400_B2
  article-title: Serum bilirubin and 10-year mortality risk in a Belgian population
  publication-title: Cancer Causes Control
  doi: 10.1023/A:1013794407325
– volume: 32
  start-page: 360
  year: 2011
  ident: 2021113010282006400_B18
  article-title: Relationship between unconjugated hyperbilirubinemia and lipoprotein spectrum
  publication-title: Neuro. Endocrinol. Lett.
– volume: 52
  start-page: 193
  year: 2012
  ident: 2021113010282006400_B30
  article-title: Bilirubin and beyond: a review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection
  publication-title: Prog. Lipid Res.
  doi: 10.1016/j.plipres.2012.11.001
– volume: 265
  start-page: 275
  year: 2009
  ident: 2021113010282006400_B38
  article-title: Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS)
  publication-title: J. Intern. Med.
  doi: 10.1111/j.1365-2796.2008.02016.x
– volume: 228
  start-page: 568
  year: 2003
  ident: 2021113010282006400_B1
  article-title: Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies
  publication-title: Exp. Biol. Med.
  doi: 10.1177/15353702-0322805-29
– volume: 112
  start-page: 1030
  year: 2005
  ident: 2021113010282006400_B15
  article-title: Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.104.528802
– volume: 22
  start-page: 302
  year: 2011
  ident: 2021113010282006400_B25
  article-title: Serum amyloid A in atherosclerosis
  publication-title: Curr. Opin. Lipidol.
  doi: 10.1097/MOL.0b013e3283488c39
– volume: 17
  start-page: 565
  year: 2007
  ident: 2021113010282006400_B40
  article-title: Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A – new risk factors and targets for therapy
  publication-title: Nutr. Metab. Cardiovasc. Dis.
  doi: 10.1016/j.numecd.2007.02.010
– volume: 6
  start-page: 841
  year: 2004
  ident: 2021113010282006400_B8
  article-title: Antioxidant activities of bile pigments
  publication-title: Antioxid. Redox Signaling
– volume: 22
  start-page: 841
  year: 2007
  ident: 2021113010282006400_B33
  article-title: Urinary excretion of oxidative metabolites of bilirubin in subjects with Gilbert syndrome
  publication-title: J. Gastroenterol. Hepatol.
  doi: 10.1111/j.1440-1746.2006.04564.x
SSID ssj0023232
Score 2.3831353
Snippet Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 257
SubjectTerms Adiposity
Adult
Aging - blood
Animals
Bilirubin - blood
Biomarkers - blood
Cardiovascular Diseases - blood
Case-Control Studies
Disease Models, Animal
Female
Gilbert Disease - blood
Humans
Inflammation - blood
Lipid Metabolism
Lipoproteins - blood
Male
Middle Aged
Rats
Rats, Gunn
Young Adult
Title Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome
URI https://www.ncbi.nlm.nih.gov/pubmed/23566065
https://www.proquest.com/docview/1351608142
Volume 125
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIiEuiDddHjICCXEIJM7DzhGhXVZod0GilXqLHNuLIpWmatPL_oI98ZuZsZ0XFGnhEqVRYleZT9NvpjPfEPKaR1JzI7IAAto4SHhoAplhDv4iKxnTZcqVVfs8z07myedFuphMfg6qlnZN-U5d7u0r-R-rwjWwK3bJ_oNlu0XhApyDfeEIFobjtWz81Yks2GpBbBMB3xDY5hSDikrIB7dWE2RZrSsgmlX9A4txNlsvuXQBaHCdi65iHUdfOcUHNa5SXff7wGqfKtTFamymf6_gwajZUlkSG-U8HyQdMH3vO23O5GY5KGSEj7CngY1d3bfeVN87so1V4O4p1xnfLVcvL5vfmwB8KgPHSuRtKsN5X8AKuOfYa2Pvuda6bNcs7bGZDh2wk7v-44cBfBMKDn9j2CycOf33sfr2-ZfieH56WsyOFrMb5CbjwMWweXzRlQwB-bQD77qv1MrdJux9v_KY4PwlarHsZXaX3PFhB_3gMHSPTMzqPrl15gsrHpCrHkoUoUQHUKItlOCEWijRHkoUoESHUKIDKNGmpmMo0R5KuJqH0pstbYH0kMyPj2YfTwI_pCNQcRo3QSZCkwtVRolJIlmmiU5FqCW4AM1TFWoDryQTkYoNN4kJGZchy7UB3iu4CYWMH5GDVb0yTwjNSiF1HhohcSgARC6CKSYggsAYQ3M-JW_bN1sor2CPg1SWha2kSFjRW2FKXnX3rp1uy967XrYGKsCt4n9lcmXq3bbAwZUZ0OWETcljZ7luHRZDDATU_fAaTz8lt3ukPyMHzWZnngONbcoXFlu_ALNsofg
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protection+from+age-related+increase+in+lipid+biomarkers+and+inflammation+contributes+to+cardiovascular+protection+in+Gilbert%27s+syndrome&rft.jtitle=Clinical+science+%281979%29&rft.au=Wallner%2C+Marlies&rft.au=Marculescu%2C+Rodrig&rft.au=Doberer%2C+Daniel&rft.au=Wolzt%2C+Michael&rft.date=2013-09-01&rft.issn=1470-8736&rft.eissn=1470-8736&rft.volume=125&rft.issue=5&rft.spage=257&rft_id=info:doi/10.1042%2FCS20120661&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0143-5221&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0143-5221&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0143-5221&client=summon